Nu Skin Enterprises (NUS)
(Delayed Data from NYSE)
$8.35 USD
-0.30 (-3.47%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $8.35 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.35 USD
-0.30 (-3.47%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $8.35 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth A Momentum A VGM
Zacks News
Nu Skin (NUS) Q2 Earnings & Sales Rise Y/Y, '18 View Lifted
by Zacks Equity Research
Nu Skin's (NUS) Q2 results gain from solid growth across most regions as well as a tick-up in sales leader and customer count.
Nu Skin Enterprises (NUS) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 20.00% and 9.80%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Q2 Earnings: Key Factors to Impact Results
by Zacks Equity Research
Nu Skin's (NUS) efforts to expand its customer base is expected to boost its Q2 results. However, margin pressure is likely to dent its bottom line.
HELE vs. NUS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HELE vs. NUS: Which Stock Is the Better Value Option?
Can Solid Sales Endeavors Fuel Nu Skin (NUS) Q1 Earnings?
by Zacks Equity Research
We expect Nu Skin (NUS) to continue gaining from its efforts to strengthen customer base and drive sales. This includes social media activities to help sales leaders and solid product strategies.
These Cosmetic Stocks Scale Fresh Highs: More Room to Run?
by Zacks Equity Research
Constant innovations, product launches and effective initiatives have been favoring Estee Lauder (EL) and Nu Skin. These stocks hit 52-week high yesterday.
Avon (AVP) Tops Q4 Earnings Despite Soft Sales, Stock Up
by Zacks Equity Research
Avon Products Inc. (AVP) reports positive earnings surprise in fourth-quarter 2017, following five straight quarters of negative surprise.
Coty (COTY) Stock Rallies on Q2 Earnings Beat & Y/Y Growth
by Zacks Equity Research
Coty(COTY) 2Q18 earnings and sales grow year over year. This marks the company's second and fourth straight quarter of earnings and sales beat. respectively.
Big Lots (BIG) Touches a 52-Week High: Can it Surge Higher?
by Zacks Equity Research
Big Lots (BIG) hit a 52-week high on Jan 26 driven by its robust initiatives and solid earnings history. Also, the company has shown impressive comps growth.
5 Best Value Picks Based on PEG Ratio
by Zacks Equity Research
For investors looking to escape value traps, it is also vital to determine where the stock is headed in the next 12 to 24 months.
Find Out What's Behind the Doom of Avon (AVP) Stock
by Zacks Equity Research
Dismal earnings trend and fall in Active Representatives have been major concerns for Avon Products Inc. (AVP), which has been losing investor confidence.
Dean Foods (DF) Recovers on Strategic Actions: Time to Hold?
by Zacks Equity Research
Dean Foods Company (DF) seems to be gaining momentum driven by its smart volume initiative; efforts to strengthen brands and diversify portfolio as well as progress on the comprehensive productivity program.
Will Boston Beer's Efforts to Drive Long-Term Growth Succeed?
by Zacks Equity Research
Boston Beer (SAM) is gaining from its strategic initiatives, cost savings, innovations and acquisitions, amid tough competition and soft depletions.
Nu Skin (NUS) Reports In-Line Q3 Earnings, Trims Guidance
by Zacks Equity Research
Nu Skin's (NUS) third-quarter 2017 results hurt by lower sales leaders and weak performance in several regions. Consequently, management trims outlook for the full year.
Will Avon's (AVP) Strategic Plans Hint at Q3 Earnings Beat?
by Zacks Equity Research
Avon (AVP) has been struggling with waning Active Representatives for a while now. However, the company's Transformation Plan is encouraging.
Will Product Launches Aid Nu Skin (NUS) in Q3 Earnings?
by Zacks Equity Research
Nu Skin (NUS) grapples with currency fluctuations and low revenues from Mainland China. However, it remains committed to innovation and product launches.
Nu Skin (NUS) Up 2.4% on Raised Q3 Sales and Profit View
by Zacks Equity Research
Nu Skin (NUS) raised its outlook for the third quarter of 2017. We believe its efforts to innovate products to boost sales is doing the trick for the company.
Unilever's Mae Terra Buyout to Expand Organic Food Business
by Zacks Equity Research
Unilever (UL) has been clinching deals to shape its portfolio to growth sustainably. The acquisition of Mae Terra is a step toward the same.
Tyson Foods Raises Earnings View, Restructuring On Track
by Zacks Equity Research
Tyson Foods (TSN) raises earnings outlook for fiscal 2017, backed by an improved Beef segment. The company will also undertake job cuts to induce financial efficiency.
Unilever (UL) Buys Carver Korea to Expand Beauty Business
by Zacks Equity Research
Unilever (UL) has been striking many deals in the past to fortify its position in the global beauty portfolio. The acquisition of Carver Korea is another step toward strengthening its portfolio.
Nu Skin or Inter Parfums: Which Cosmetic Stock Looks Better?
by Zacks Equity Research
The cosmetic industry is in huge demand currently. In this backdrop, which of these two key cosmetics giants -- Nu Skin (NUS) and Inter Parfums (IPAR) -- will perform better?
Why Coty (COTY) Should be Dropped From Your Portfolio Now?
by Zacks Equity Research
Coty (COTY) has been depicting sluggish performance over the past few quarters owing to its weak segments and rising operational expenses.
Here's Why You Should Hold Tyson Foods in Your Portfolio Now
by Zacks Equity Research
Tyson Foods (TSN) has been gaining from the rising demand of its protein packed products and strategic acquisitions.
The Zacks Analyst Blog Highlights: Estee Lauder, Nu Skin Enterprises, Coty and Avon Products
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Estee Lauder, Nu Skin Enterprises, Coty and Avon Products
Shuffle Your Portfolio: Buy or Avoid These Cosmetics Stocks
by Zacks Equity Research
Cosmetics industry is doing well and so investors should shuffle their portfolios and buy/avoid these stocks.